Risk Assessment After Acute Upper Gastrointestinal Haemorrhage in Cirrhosis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

500 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-01-10

Study Completion Date

2020-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In previous studies, the investigators used retrospective analysis of cases of acute upper gastrointestinal bleeding in patients with liver cirrhosis from the Fifth Medical Center of the General Hospital of Beijing PLA, China from January 2018 to May 2019. The investigators performed univariate and multivariate analyses of rebleeding risk and death risk based on all data. Then, based on the analysis of 85% of the sampled data, the investigators randomly selected 85% of the patient data to build a model, and then used the remaining 15% of the patient data for model validation. Re-bleeding risk scores and death risk scores were established, respectively.

This study intends to prospectively verify the two risk scoring systems described above. After statistical calculations, about 500 patients with liver cirrhosis who plan to undergo emergency gastroscopy for acute upper gastrointestinal bleeding within the next 5 months at the Fifth Medical Center of Beijing General Hospital of China performed in adult patients. The investigators will exclude patients with incomplete or lost follow-up records. Perform patient self-control,using the existing upper gastrointestinal bleeding risk scores (AIMS65, Rockall, and Blatchford) and the previous scoring system model separately, compared with the actual rebleeding rate and mortality for comparison. To verify and revise the rebleeding risk score and death risk score that the investigators constructed earlier.The data were statistical processed by a professional statistician.

The establishment of an acute upper gastrointestinal bleeding rebleeding and death risk scoring system for patients with liver cirrhosis can help distinguish patients with high or low risk of rebleeding or death to determine the patient's treatment needs.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Upper Endoscopy in Cirrhotic Patients With Upper Gastrointestinal Bleeding

NCT06214234

Esophageal Varices

NOT_YET_RECRUITING NA

Predictive and Prognostic Significance of Age,Blood Tests,Comorbidities(ABC) Score,Cologne Watch(C-watch)Score and Rockall Score for Risk of Variceal Re-bleeding Among Cirrhotic Patients

NCT06335186

Upper Gastrointestinal Variceal Bleeding in Cirrhotic Patients

RECRUITING

Timing of Endoscopy in Cirrhotic Patients with Acute Variceal Bleeding

NCT06031402

Acute Upper Gastrointestinal Bleeding Acute Variceal Bleeding

RECRUITING NA

Effect of Re-education on Rebleeding Rate After Endoscopic Treatment in Liver Cirrhosis

NCT05302661

Liver Cirrhosis Esophageal Varices Bleeding Gastric Variceal Bleeding +1 more

UNKNOWN NA

Preemptive TIPS for Gastric Variceal Bleeding in Patients With Cirrhosis

NCT06122792

Portal Hypertension Gastric Varices Bleeding Portosystemic Shunt

NOT_YET_RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In previous studies, the investigators used retrospective analysis of cases of acute upper gastrointestinal bleeding in patients with liver cirrhosis from the Fifth Medical Center of the General Hospital of Beijing PLA, China from January 2018 to May 2019. The survey and return visits were completed by the patient's clinician, and the subject researcher was responsible for reviewing and including a complete questionnaire for eligible patients. The database includes demographic information, vital signs and other key clinical manifestations, endoscopic findings, laboratory test results, imaging studies and complications, and rebleeding and deaths within 42 days. Covers known risk factors for rebleeding and death.

First, the investigators performed univariate and multivariate analyses of rebleeding risk and death risk based on all data. Second, based on the analysis of 85% of the sampled data, the investigators randomly selected 85% of the patient data to build a model, and then used the remaining 15% of the patient data for model validation. Re-bleeding risk scores and death risk scores were established respectively.

This study intends to prospectively verify the two risk scoring systems described above. After statistical calculations, about 500 patients with liver cirrhosis who plan to undergo emergency gastroscopy for acute upper gastrointestinal bleeding within the next 5 months at the Fifth Medical Center of Beijing General Hospital of China Performed in adult patients. the investigators will exclude patients with incomplete or lost follow-up records. One researcher was responsible for patient identification and data collection during the initial review, and one researcher performed subsequent data entry, which was statistical processed by a professional statistician.

Perform patient self-control,using the existing upper gastrointestinal bleeding risk scores (AIMS65, Rockall, and Blatchford) and the previous scoring system model separately, compared with the actual rebleeding rate and mortality for comparison. To verify and revise the rebleeding risk score and death risk score that the investigators constructed earlier.

The establishment of an acute upper gastrointestinal bleeding rebleeding and death risk scoring system for patients with liver cirrhosis can help distinguish patients with high or low risk of rebleeding or death to determine the patient's treatment needs.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cirrhosis, Liver Acute Upper Gastrointestinal Hemorrhage

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patient cohort

Different risk score was used to assess the prognosis of acute upper gastrointestinal bleeding in cirrhosis.

Current risk scores

Intervention Type OTHER

Current risk scores for assessing the prognosis of acute upper gastrointestinal bleeding in cirrhosis were used.

New risk scores

Intervention Type OTHER

New risk scores for assessing the progress of acute upper gastrointestinal bleeding in cirrhosis was used.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Current risk scores

Current risk scores for assessing the prognosis of acute upper gastrointestinal bleeding in cirrhosis were used.

Intervention Type OTHER

New risk scores

New risk scores for assessing the progress of acute upper gastrointestinal bleeding in cirrhosis was used.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with histologically proven cirrhosis or clinical and ultrasonographic data compatible with the diagnosis of cirrhosis
* Above 18 years old patients
* Clinical evidence of bleeding (hematemesis and/or melena) during the previous 24 hours
* Undergo the emergency endoscopy within 2 hours at admittance to emergency room or in the general ward from the initial evaluation
* Who agree to participate in the study